Institutional Investors Sentiment Indicator of Allergan Inc (NYSE:AGN) Increases in Q4 2017

April 25, 2018 - By Migdalia James

Allergan plc (NYSE:AGN) Logo

Sentiment for Allergan Inc (NYSE:AGN)

Allergan Inc (NYSE:AGN) institutional sentiment increased to 1.25 in 2017 Q4. Its up 0.92, from 0.33 in 2017Q3. The ratio has improved, as 5 institutional investors increased and opened new positions, while 4 reduced and sold their holdings in Allergan Inc. The institutional investors in our partner’s database reported: 44,210 shares, down from 54,287 shares in 2017Q3. Also, the number of institutional investors holding Allergan Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 2 Increased: 4 New Position: 1.

Allergan plc, a specialty pharmaceutical company, develops, makes, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. The company has market cap of $51.34 billion. It operates through US Specialized Therapeutics, US General Medicine, and International divisions. It currently has negative earnings. The firm offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womenÂ’s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as AlzheimerÂ’s disease.

The stock decreased 0.11% or $0.18 during the last trading session, reaching $156.72. About 880,542 shares traded. Allergan plc (NYSE:AGN) has declined 33.03% since April 25, 2017 and is downtrending. It has underperformed by 44.58% the S&P500.

Analysts await Allergan plc (NYSE:AGN) to report earnings on April, 30 before the open. They expect $3.36 EPS, up 0.30 % or $0.01 from last year’s $3.35 per share. AGN’s profit will be $1.10 billion for 11.66 P/E if the $3.36 EPS becomes a reality. After $4.86 actual EPS reported by Allergan plc for the previous quarter, Wall Street now forecasts -30.86 % negative EPS growth.

Mitchell Mcleod Pugh & Williams Inc holds 0.45% of its portfolio in Allergan plc for 3,965 shares. Frontier Investment Mgmt Co owns 14,953 shares or 0.2% of their US portfolio. Moreover, Grassi Investment Management has 0.2% invested in the company for 7,435 shares. The Texas-based Callahan Advisors Llc has invested 0.15% in the stock. Cubic Asset Management Llc, a Massachusetts-based fund reported 2,321 shares.

Allergan plc (NYSE:AGN) Ratings Coverage

Ratings analysis reveals 71% of Allergan’s analysts are positive. Out of 17 Wall Street analysts rating Allergan, 12 give it “Buy”, 0 “Sell” rating, while 5 recommend “Hold”. The lowest target is $171.0 while the high is $25500. The stock’s average target of $211.71 is 35.09% above today’s ($156.72) share price. AGN was included in 29 notes of analysts from November 1, 2017. The rating was maintained by Credit Suisse with “Outperform” on Wednesday, February 7. Mizuho maintained Allergan plc (NYSE:AGN) on Wednesday, November 1 with “Hold” rating. The firm has “Buy” rating by RBC Capital Markets given on Thursday, November 2. UBS maintained it with “Buy” rating and $250.0 target in Wednesday, January 10 report. As per Thursday, November 2, the company rating was maintained by Morgan Stanley. As per Monday, November 27, the company rating was maintained by Leerink Swann. The firm has “Buy” rating given on Thursday, March 1 by Credit Suisse. The firm has “Buy” rating by Leerink Swann given on Wednesday, January 3. Wells Fargo maintained the stock with “Buy” rating in Thursday, November 2 report. The firm has “Buy” rating by Leerink Swann given on Wednesday, February 7.

Allergan plc (NYSE:AGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.